

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7704180

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
LARA C. CZABANIUK	06/18/2021
TIMOTHY HOPPER	07/15/2021
JANE PANTELEEV	06/09/2021
GWENAELLA RESCOURIO	06/18/2021
VINCENT SANTORA	06/07/2021
HAOXUAN WANG	06/07/2021
RYAN D. WHITE	06/07/2021
ALICE R. WONG	06/12/2021
YONGWEI WU	09/23/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AMGEN INC.
<b>Street Address:</b>	ONE AMGEN CENTER DRIVE
<b>City:</b>	THOUSAND OAKS
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	91320
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	18072501
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)275-8374
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6177287100
<b>Email:</b>	BOSpatents@dechert.com, Daphne.Cashion@dechert.com
<b>Correspondent Name:</b>	DECHERT LLP
<b>Address Line 1:</b>	ONE INTERNATIONAL PLACE, 40TH FLOOR
<b>Address Line 2:</b>	100 OLIVER STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	403433-005USC1 (193334)
<b>NAME OF SUBMITTER:</b>	ANDREA L.C. REID

PATENT

<b>SIGNATURE:</b>	/Andrea L.C. Reid/
<b>DATE SIGNED:</b>	12/20/2022
<b>Total Attachments: 24</b> source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page1.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page2.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page3.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page4.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page5.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page6.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page7.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page8.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page9.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page10.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page11.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page12.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page13.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page14.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page15.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page16.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page17.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page18.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page19.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page20.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page21.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page22.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page23.tif source=403433-005USC1_193334_Dec-Assign_from_parent_Inv_to_Amgen#page24.tif	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Lara C. CZABANIUK**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Timothy HOPPER**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Jane PANTELEEV**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Gwenaella RESCOURIO**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Vincent SANTORA**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Haoxuan WANG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Ryan D. WHITE**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Alice R. WONG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Yongwei WU**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

are inventors of the invention described and claimed in **"HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE"** and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of May 4, 2021, and

are also aware of the following priority applications:

**63/019,772**, filing date of May 4, 2020

WHEREAS, **AMGEN INC.** (hereinafter termed "Assignee"), having a place of business at One Amgen Center Drive, Thousand Oaks, California 91320, USA, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents

granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

AMGEN INC. ("Assignee")

By: Stuart L. Watt

Name: Stuart L. Watt

Title: VP Intellectual Property & Litigation

Date: Jan. 13, 2022

WITNESSES

Signature: Joni M. Puccio

Signature: Shawn Updegraff

By: <u>Lara C. CZABANIUK</u> Date: <u>6/18/21</u> WITNESSES: <u>Eric McNeill</u> Signature: <u>[Signature]</u> Signature: _____	By: <u>Timothy HOPPER</u> Date: _____ WITNESSES: _____ Signature: _____ Signature: _____
By: <u>Jane PANTELEEV</u> Date: _____ WITNESSES: _____ Signature: _____ Signature: _____	By: <u>Gwensella RESCOURIO</u> Date: _____ WITNESSES: _____ Signature: _____ Signature: _____
By: <u>Vincent SANTORA</u> Date: _____ WITNESSES: _____ Signature: _____ Signature: _____	By: <u>Haoxuan WANG</u> Date: _____ WITNESSES: _____ Signature: _____ Signature: _____

By: <u>Ryan D. White</u> Ryan D. WHITE	By: _____ Alice R. WONG
Date: <u>June 7<sup>th</sup>, 2021</u>	Date: _____
WITNESSES: Signature: <u>Amy C.S. Whit</u>	WITNESSES: Signature: _____
Signature: <u>June 7<sup>th</sup>, 2021</u>	Signature: _____
By: _____ Yongwei WU	
Date: _____	
WITNESSES: Signature: _____	
Signature: _____	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Lara C. CZABANIUK**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Timothy HOPPER**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Jane PANTELEEV**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Gwenaella RESCOURIO**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Vincent SANTORA**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Haoxuan WANG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Ryan D. WHITE**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Alice R. WONG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Yongwei WU**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

are inventors of the invention described and claimed in "**HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**" and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of May 4, 2021, and

are also aware of the following priority applications:

**63/019,772**, filing date of **May 4, 2020**

WHEREAS, **AMGEN INC.** (hereinafter termed "Assignee"), having a place of business at **One Amgen Center Drive, Thousand Oaks, California 91320, USA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents

granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

**AMGEN INC. ("Assignee")**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_


Date: \_\_\_\_\_

*WITNESSES*

*Signature:* \_\_\_\_\_

*Signature:* \_\_\_\_\_



By: _____ <b>Lara C. CZABANIUK</b>	By:  <b>Timothy HOPPER</b>
Date: _____	Date: <u>07/15/2021</u>
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____
By: _____ <b>Jane PANTELEEV</b>	By: _____ <b>Gwenaelle RESCOURIO</b>
Date: _____	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____
By: _____ <b>Vincent SANTORA</b>	By: _____ <b>Haoxuan WANG</b>
Date: _____	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____

<p>By: _____ <b>Ryan D. WHITE</b></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>	<p>By: <u>Alice Wong</u> Alice E. WONG</p> <p>Date: <u>6/12/21</u></p> <p>WITNESSES:</p> <p>Signature: <u>[Signature]</u></p> <p>Signature: _____</p>
<p>By: _____ <b>Yongwei WU</b></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Lara C. CZABANIUK, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Timothy HOPPER, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Jane PANTELEEV, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Gwenaella RESCOURIO, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Vincent SANTORA, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Haoxuan WANG, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Ryan D. WHITE, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Alice R. WONG, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

**Yongwei WU, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;**

are inventors of the invention described and claimed in "**HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**" and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of May 4, 2021, and

are also aware of the following priority applications:

**63/019,772, filing date of May 4, 2020**

WHEREAS, **AMGEN INC.** (hereinafter termed "Assignee"), having a place of business at **One Amgen Center Drive, Thousand Oaks, California 91320, USA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents

granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

**AMGEN INC. ("Assignee")**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: \_\_\_\_\_

*WITNESSES*

*Signature:* \_\_\_\_\_

*Signature:* \_\_\_\_\_

By: _____ <b>Lara C. CZABANIUK</b>	By: _____ <b>Timothy HOPPER</b>
Date: _____	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____
By: _____  <b>Jane PANTELEEV</b>	By: _____ <b>Gwenaella RESCOURIO</b>
Date: <u>06/09/2021</u>	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____
By: _____ <b>Vincent SANTORA</b>	By: _____ <b>Haoxuan WANG</b>
Date: _____	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____

<p>By: _____  <b>Ryan D. WHITE</b></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>	<p>By: _____  <b>Alice R. WONG</b></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>
<p>By: <u><i>Yongwei Wu</i></u>  <b>Yongwei Wu</b></p> <p>Date: <u><i>09/23/2021</i></u></p> <p>WITNESSES: <u><i>ying liang wu</i></u></p> <p>Signature: _____</p> <p>Signature: _____</p>	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Lara C. CZABANIUK**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Timothy HOPPER**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Jane PANTELEEV**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Gwenaella RESCOURIO**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Vincent SANTORA**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Haoxuan WANG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Ryan D. WHITE**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Alice R. WONG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Yongwei WU**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

are inventors of the invention described and claimed in "**HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**" and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of May 4, 2021, and

are also aware of the following priority applications:

**63/019,772**, filing date of **May 4, 2020**

WHEREAS, **AMGEN INC.** (hereinafter termed "Assignee"), having a place of business at **One Amgen Center Drive, Thousand Oaks, California 91320, USA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents

granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

**AMGEN INC.** ("Assignee")

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: \_\_\_\_\_

*WITNESSES*

*Signature:* \_\_\_\_\_

*Signature:* \_\_\_\_\_



<p>By: <u>Lara C. CZABANIUK</u></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>	<p>By: <u>Timothy HOPPER</u></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>
<p>By: <u>Jane PANTELEEV</u></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>	<p>By: <u>Gwenaelle RESCOURIO</u></p> <p>Date: <u>06/18/2021</u></p> <p>WITNESSES:</p> <p>Signature: <u>Elizabeth Bradley</u></p> <p>Signature: <u>[Signature]</u></p>
<p>By: <u>Vincent SANTORA</u></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>	<p>By: <u>Haoxuan WANG</u></p> <p>Date: _____</p> <p>WITNESSES:</p> <p>Signature: _____</p> <p>Signature: _____</p>

<p>By: _____ Ryan D. WHITE</p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>	<p>By: _____ Alice R. WONG</p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>
<p>By: _____ Yongwei WU</p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Lara C. CZABANIUK**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Timothy HOPPER**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Jane PANTELEEV**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Gwenaella RESCOURIO**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Vincent SANTORA**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Haoxuan WANG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Ryan D. WHITE**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Alice R. WONG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Yongwei WU**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

are inventors of the invention described and claimed in "**HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**" and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of May 4, 2021, and

are also aware of the following priority applications:

**63/019,772**, filing date of **May 4, 2020**

WHEREAS, **AMGEN INC.** (hereinafter termed "Assignee"), having a place of business at **One Amgen Center Drive, Thousand Oaks, California 91320, USA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents

granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

**AMGEN INC.** ("Assignee")

By: \_\_\_\_\_

Name: \_\_\_\_\_


Title: \_\_\_\_\_

Date: \_\_\_\_\_

*WITNESSES*

*Signature:* \_\_\_\_\_

*Signature:* \_\_\_\_\_

By: <u>Lara C. CZABANIUK</u> Date: _____  WITNESSES: Signature: _____  Signature: _____	By: <u>Timothy HOPPER</u> Date: _____  WITNESSES: Signature: _____  Signature: _____
By: <u>Jane PANTELEEV</u> Date: _____  WITNESSES: Signature: _____  Signature: _____	By: <u>Gwenaelle RESCOURIO</u> Date: _____  WITNESSES: Signature: _____  Signature: _____
By: <u></u> Date: <u>6/7/21</u>  WITNESSES: Signature: _____  Signature: _____	By: <u>Haoxuan WANG</u> Date: _____  WITNESSES: Signature: _____  Signature: _____

<p>By: _____ <b>Ryan D. WHITE</b></p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>	<p>By: _____ <b>Alice R. WONG</b></p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>
<p>By: _____ <b>Yongwei WU</b></p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>	

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Lara C. CZABANIUK**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Timothy HOPPER**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Jane PANTELEEV**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Gwenaella RESCOURIO**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Vincent SANTORA**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Haoxuan WANG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Ryan D. WHITE**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Alice R. WONG**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

**Yongwei WU**, of c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA;

are inventors of the invention described and claimed in "**HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE**" and hereby execute an application for a patent of the United States, having Application No. 17/302,502, filing date of May 4, 2021, and

are also aware of the following priority applications:

**63/019,772**, filing date of **May 4, 2020**

WHEREAS, **AMGEN INC.** (hereinafter termed "Assignee"), having a place of business at **One Amgen Center Drive, Thousand Oaks, California 91320, USA**, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents

granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

**AMGEN INC.** ("Assignee")

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_




Date: \_\_\_\_\_

*WITNESSES*

*Signature:* \_\_\_\_\_

*Signature:* \_\_\_\_\_



By: _____ <b>Lara C. CZABANIUK</b>	By: _____ <b>Timothy HOPPER</b>
Date: _____	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____
By: _____ <b>Jane PANTELEEV</b>	By: _____ <b>Gwenaella RESCOURIO</b>
Date: _____	Date: _____
WITNESSES:	WITNESSES:
Signature: _____	Signature: _____
Signature: _____	Signature: _____
By: _____ <b>Vincent SANTORA</b>	By: _____  <b>Haoxuan WANG</b>
Date: _____	Date: <u>June 7<sup>th</sup> 2021</u>
WITNESSES:	WITNESSES:
Signature: _____	Signature: 
Signature: _____	Signature: 

<p>By: _____ <b>Ryan D. WHITE</b></p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>	<p>By: _____ <b>Alice R. WONG</b></p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>
<p>By: _____ <b>Yongwei WU</b></p> <p>Date: _____</p> <p><i>WITNESSES:</i></p> <p><i>Signature:</i> _____</p> <p><i>Signature:</i> _____</p>	